These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33396393)

  • 1. Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.
    Wang TH; Wu CC; Huang KY; Leu YL; Yang SC; Chen CL; Chen CY
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin.
    Huang KY; Wang TH; Chen CC; Leu YL; Li HJ; Jhong CL; Chen CY
    Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.
    Yamaura T; Muto S; Mine H; Takagi H; Watanabe M; Ozaki Y; Inoue T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
    Oncol Lett; 2020 Jun; 19(6):4169-4176. PubMed ID: 32391110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation
    Lai M; Zhang T; Chen H; Song P; Tong L; Chen J; Liu Y; Ning Y; Feng F; Li Y; Tang H; Chen Y; Fang Y; Lu X; Geng M; Ding K; Yu K; Ding J; Xie H
    J Cancer; 2023; 14(1):152-162. PubMed ID: 36605493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGFR
    Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
    Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Hidaka N; Iwama E; Kubo N; Harada T; Miyawaki K; Tanaka K; Okamoto I; Baba E; Akashi K; Sasaki H; Nakanishi Y
    Lung Cancer; 2017 Jun; 108():75-82. PubMed ID: 28625653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
    Zhao P; Yao MY; Zhu SJ; Chen JY; Yun CH
    Biochem Biophys Res Commun; 2018 Jul; 502(3):332-337. PubMed ID: 29802850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
    Choi YJ; Kim DS; Hoon Sung Y; Kim DH; Im K; Lee H; Lee CW; Cho J; Min J; Woo DC; Kim SE; Lee S; Kong YJ; Ryu HC; Kim JS; Rengasamy R; Ji W; Choi CM; Lee JC; Rho JK
    Cancer Res; 2022 Jun; ():. PubMed ID: 35700239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
    Lin CY; Huang KY; Lin YC; Yang SC; Chung WC; Chang YL; Shih JY; Ho CC; Lin CA; Shih CC; Chang YH; Kao SH; Yang PC
    Cancer Lett; 2021 Jun; 508():76-91. PubMed ID: 33775711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M,
    Chang Y; Liu S; Jiang Y; Hua L; Wen L
    Respir Med Case Rep; 2022; 36():101582. PubMed ID: 35106279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
    Patel H; Pawara R; Surana S
    Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
    Niederst MJ; Hu H; Mulvey HE; Lockerman EL; Garcia AR; Piotrowska Z; Sequist LV; Engelman JA
    Clin Cancer Res; 2015 Sep; 21(17):3924-33. PubMed ID: 25964297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.
    Duggirala KB; Lee Y; Lee K
    Biomol Ther (Seoul); 2022 Jan; 30(1):19-27. PubMed ID: 34074804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
    Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
    Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review.
    Mansour MA; AboulMagd AM; Abbas SH; Abdel-Rahman HM; Abdel-Aziz M
    RSC Adv; 2023 Jun; 13(27):18825-18853. PubMed ID: 37350862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
    Wang X; Goldstein D; Crowe PJ; Yang JL
    Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer.
    Sun P; Qu Y; Wang Y; Wang J; Wang X; Sheng J
    J Cancer; 2021; 12(13):3900-3908. PubMed ID: 34093797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired
    He W; Tong L; Yang W; Yuan Y; Li Y; Tang W
    Front Oncol; 2024; 14():1298389. PubMed ID: 38903714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.